A Delaware jury found that Parse Biosciences, a Qiagen subsidiary, willfully infringed three Scale Biosciences patents that were acquired by 10x Genomics in 2025, while also upholding the validity of those patents. 10x said it was awarded more than $4.8 million in damages for Parse Evercode whole transcriptome sales from February 2021 through June 30, 2026. The verdict also preserved 10x’s ability to seek enhanced damages, attorneys’ fees, and a permanent injunction to stop further infringement in the US. The jury invalidated a related fourth patent that had been licensed to Scale and used in the suit, highlighting the complexity of the patent landscape around single-cell barcoding and epitope mapping. The decision is a notable reference point for enforcement strategies in single-cell genomics, where platform differentiation can depend as much on IP protections as on technical performance.